The aim of this prospective study was to evaluate the value of 18F-FDG PET for the
assessment of chemotherapy response in patients with non–small cell lung cancer …

PET/CT with the glucose analog 18F-FDG has several potential applications for monitoring
tumor response to therapy in patients with non–small cell lung cancer (NSCLC). A …

Purpose: To prospectively evaluate the use of positron emission tomography with the
glucose analog fluorodeoxyglucose (FDG-PET) to predict response to chemotherapy in …

The potential of 18F-FDG PET changes was evaluated for prediction of response to
concomitant chemoradiotherapy in patients with locally advanced non–small cell lung …

Abstract PET using 18F-fluorodeoxyglucose (FDG) is increasingly applied to monitor the
response of malignant tumors to radiotherapy and chemotherapy. The aim of this study was …

Purpose The aim of this study was to prospectively evaluate the role of various quantitative
and semiquantitative metabolic parameters derived from dynamic and static baseline 18 F …

PET and 18F-FDG have the potential to follow the early metabolic response to
chemotherapy in patients with non–small cell lung cancer and to predict success or failure of …

OBJECTIVES: To investigate the changes in tumour proliferation (using FLT), metabolism
(using FDG), and hypoxia (using F-miso) during curative (chemo-) radiotherapy (RT) in …

Purpose Among patients with advanced non-small cell lung cancer (NSCLC), identification
of a subgroup of patients for immediate maintenance treatment after first-line chemotherapy …

PET using 18F-FDG is a promising technique to monitor response in oncology.
Unfortunately, a multitude of analytic methods is in use. To date, it is not clear whether …